Malaria vaccine development: Persistent challenges

Current Opinion in Immunology

Volumn 24, Issue 3, 2012, Pages 324-331

  Vaughan, Ashley M ^a   Kappe, Stefan HI ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; GAMMA INTERFERON; INTERLEUKIN 10; MALARIA VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; APICOMPLEXA; BLOOD PARASITE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS PROTECTION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; MALARIA FALCIPARUM; MEMORY T LYMPHOCYTE; MEROZOITE; NONHUMAN; PARASITE TRANSMISSION; PARASITEMIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REVIEW; SCHIZONT; SPOROZOITE;

ANIMALS; ERYTHROCYTES; HUMANS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; PLASMODIUM;

EID: 84862684539     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.03.009     Document Type: Review

References (59)

1. Murray C.J., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., Fullman N., Naghavi M., Lozano R., Lopez A.D. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.
2. WHO World Malaria Report 2010 2010.
3. Singh H., Parakh A., Basu S., Rath B. Plasmodium vivax malaria: is it actually benign?. J Infect Public Health 2011, 4:91-95.
4. Price R.N., Tjitra E., Guerra C.A., Yeung S., White N.J., Anstey N.M. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007, 77:79-87.
5. Baird J.K. Neglect of Plasmodium vivax malaria. Trends Parasitol 2007, 23:533-539.
6. Lee K.S., Divis P.C., Zakaria S.K., Matusop A., Julin R.A., Conway D.J., Cox-Singh J., Singh B. Plasmodium knowlesi: reservoir hosts and tracking the emergence in humans and macaques. PLoS Pathog 2011, 7:e1002015.
7. Doolan D.L., Dobano C., Baird J.K. Acquired immunity to malaria. Clin Microbiol Rev 2009, 22:13-36.
8. Portugal S., Carret C., Recker M., Armitage A.E., Goncalves L.A., Epiphanio S., Sullivan D., Roy C., Newbold C.I., Drakesmith H., et al. Host-mediated regulation of superinfection in malaria. Nat Med 2011, 17:732-737.
9. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
10. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973, 266:169-177.
11. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., van de Vegte-Bolmer M., van Schaijk B., Teelen K., Arens T., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361:468-477.
12. Roestenberg M., Teirlinck A.C., McCall M.B., Teelen K., Makamdop K.N., Wiersma J., Arens T., Beckers P., van Gemert G., van de Vegte-Bolmer M., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377:1770-1776.
13. Hoffman S.L., Billingsley P.F., James E., Richman A., Loyevsky M., Li T., Chakravarty S., Gunasekera A., Li M., Stafford R., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vacc 2010, 6.
14. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., Gunasekera A., Chakravarty S., James E.R., Sedegah M., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8 T cell immunity. Science 2011, 334:475-480.
15. Kappe S.H., Mikolajczak S.A. Immunology. Another shot at a malaria vaccine. Science 2011, 334:460-461.
16. VanBuskirk K.M., O'Neill M.T., De La Vega P., Maier A.G., Krzych U., Williams J., Dowler M.G., Sacci J.B., Kangwanrangsan N., Tsuboi T., et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A 2009, 106:13004-13009.
17. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9:451-462.
18. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., Schwenk R., Nielsen R.A., Debebe Z., Pinelis E., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
19. Schwenk R., Lumsden J.M., Rein L.E., Juompan L., Kester K.E., Heppner D.G., Krzych U. Immunization with the RTS,S/AS malaria vaccine induces IFN-gamma(+)CD4 T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge. Vaccine 2011, 29:8847-8854.
20. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., Methogo B.G., Doucka Y., Flamen A., Mordmuller B., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
21. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., Mshamu S., Lang T., Gould J., Dubois M.C., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008, 359:2521-2532.
22. Olotu A., Lusingu J., Leach A., Lievens M., Vekemans J., Msham S., Lang T., Gould J., Dubois M.C., Jongert E., et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011, 11:102-109.
23. Nussenzweig V., Good M.F., Hill A.V. Mixed results for a malaria vaccine. Nat Med 2011, 17:1560-1561.
24. + T effector memory cells protect against liver-stage malaria. J Immunol 2011, 187:1347-1357.
25. Bakshi S., Imoukhuede E.B. Malaria Vectored Vaccines Consortium (MVVC). Hum Vacc 2010, 6:433-434.
26. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., Goodman A.L., Edwards N.J., Reyes-Sandoval A., Bird P., et al. Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012.
27. Tsuji M. A retrospective evaluation of the role of T cells in the development of malaria vaccine. Exp Parasitol 2010, 126:421-425.
28. Wizel B., Houghten R.A., Parker K.C., Coligan J.E., Church P., Gordon D.M., Ballou W.R., Hoffman S.L. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med 1995, 182:1435-1445.
29. Butler N.S., Schmidt N.W., Harty J.T. Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J Immunol 2010, 184:2528-2538.
30. Frevert U., Moreno A., Calvo-Calle J.M., Klotz C., Nardin E. Imaging effector functions of human cytotoxic CD4(+) T cells specific for Plasmodium falciparum circumsporozoite protein. Int J Parasitol 2008.
31. + T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J Immunol 2009, 183:5870-5878.
32. + T cell responses against malaria liver stage parasites. PLoS Pathog 2010, 6:e1000877.
33. Cockburn I.A., Tse S.W., Radtke A.J., Srinivasan P., Chen Y.C., Sinnis P., Zavala F. Dendritic cells and hepatocytes use distinct pathways to process protective antigen from Plasmodium in vivo. PLoS Pathog 2011, 7:e1001318.
34. Schmidt N.W., Podyminogin R.L., Butler N.S., Badovinac V.P., Tucker B.J., Bahjat K.S., Lauer P., Reyes-Sandoval A., Hutchings C.L., Moore A.C., et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A 2008, 105:14017-14022.
35. Schmidt N.W., Butler N.S., Harty J.T. Plasmodium-host interactions directly influence the threshold of memory CD8 T cells required for protective immunity. J Immunol 2011, 186:5873-5884.
36. Schmidt N.W., Butler N.S., Badovinac V.P., Harty J.T. Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 2010, 6:e1000998.
37. Schmidt N.W., Harty J.T. Cutting edge: attrition of Plasmodium-specific memory CD8 T cells results in decreased protection that is rescued by booster immunization. J Immunol 2011, 186:3836-3840.
38. Roberts L., Enserink M. Malaria. Did they really say ... eradication?. Science 2007, 318:1544-1545.
39. Ellis R.D., Sagara I., Doumbo O., Wu Y. Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vacc 2010, 6:627-634.
40. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., Anderson K., Mahakunkijcharoen Y., Martin L.B., Wilson D., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
41. Takala S.L., Coulibaly D., Thera M.A., Batchelor A.H., Cummings M.P., Escalante A.A., Ouattara A., Traore K., Niangaly A., Djimde A.A., et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 2009, 1:2ra5.
42. Spring M.D., Cummings J.F., Ockenhouse C.F., Dutta S., Reidler R., Angov E., Bergmann-Leitner E., Stewart V.A., Bittner S., Juompan L., et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 2009, 4:e5254.
43. Crosnier C., Bustamante L.Y., Bartholdson S.J., Bei A.K., Theron M., Uchikawa M., Mboup S., Ndir O., Kwiatkowski D.P., Duraisingh M.T., et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011, 480:534-537.
44. Rodriguez M., Lustigman S., Montero E., Oksov Y., Lobo C.A. PfRH5: a novel reticulocyte-binding family homolog of Plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLoS ONE 2008, 3:e3300.
45. Cohen S., Mc G.I., Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
46. Wipasa J., Suphavilai C., Okell L.C., Cook J., Corran P.H., Thaikla K., Liewsaree W., Riley E.M., Hafalla J.C. Long-lived antibody and B cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog 2010, 6:e1000770.
47. Langhorne J., Ndungu F.M., Sponaas A.M., Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008, 9:725-732.
48. Wipasa J., Okell L., Sakkhachornphop S., Suphavilai C., Chawansuntati K., Liewsaree W., Hafalla J.C., Riley E.M. Short-lived IFN-gamma effector responses, but long-lived IL-10 memory responses, to malaria in an area of low malaria endemicity. PLoS Pathog 2011, 7:e1001281.
49. Dinglasan R.R., Jacobs-Lorena M. Flipping the paradigm on malaria transmission-blocking vaccines. Trends Parasitol 2008, 24:364-370.
50. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., Fay M.P., Narum D., Rausch K., Miles A.P., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 3:e2636.
51. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., Long C.A., Lambert L., Miles A.P., Wang J., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23:3131-3138.
52. Miyata T., Harakuni T., Sugawa H., Sattabongkot J., Kato A., Tachibana M., Torii M., Tsuboi T., Arakawa T. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine 2011, 29:2720-2726.
53. Tachibana M., Sato C., Otsuki H., Sattabongkot J., Kaneko O., Torii M., Tsuboi T. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate. Vaccine 2012.
54. Chowdhury D.R., Angov E., Kariuki T., Kumar N. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS ONE 2009, 4:e6352.
55. Goodman A.L., Blagborough A.M., Biswas S., Wu Y., Hill A.V., Sinden R.E., Draper S.J. A viral vectored prime-boost immunization regime targeting the malaria pfs25 antigen induces transmission-blocking activity. PLoS ONE 2011, 6:e29428.
56. Suarez C.E., Noh S. Emerging perspectives in the research of bovine babesiosis and anaplasmosis. Vet Parasitol 2011, 180:109-125.
57. Sharman P.A., Smith N.C., Wallach M.G., Katrib M. Chasing the golden egg: vaccination against poultry coccidiosis. Parasite Immunol 2010, 32:590-598.
58. Morrison W.I. Progress towards understanding the immunobiology of Theileria parasites. Parasitology 2009, 136:1415-1426.
59. Baer K., Klotz C., Kappe S.H., Schnieder T., Frevert U. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog 2007, 3:e171.